Opthea Limited Sponsored ADR (OPT) Price & Analysis

Compare

198 Followers

OPT Stock Chart & Stats

$0.20

-$0.09(-2.34%)

At close: Jan 08 4:00 PM EST

$0.20

-$0.09(-2.34%)

Day’s Range― - ―

52-Week Range$0.02 - $6.30

Previous CloseN/A

Volume12.29K

Average Volume (3M)0.00

Market Cap

$477.76M

Enterprise Value$689.39M

Total Cash (Recent Filing)$172.47M

Total Debt (Recent Filing)$141.65M

Price to Earnings (P/E)―

Beta2.06

Next Earnings

Feb 26, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.20

Shares Outstanding170,997,270

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)-2.00

Price to Sales (P/S)1215.83

P/FCF Ratio-0.94

Enterprise Value/Market Cap1.44

Enterprise Value/Revenue3.78K

Enterprise Value/Gross Profit-5.81K

Enterprise Value/Ebitda-2.41

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusHold

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Bears Say

Clinical TrialsOpthea's Phase 3 COAST trial of sozinibercept in combination with Eylea for wet age-related macular degeneration failed to meet its primary endpoint, which is disappointing.

Financial SolvencyThe company could be required to pay four multiples of the amounts paid to the company upon termination of the DFA agreement, which would have a material impact on the solvency of the company.

Stock DowngradeGiven the negative readout, the stock is downgraded to MP and the price target moves from $12 to $1.

Opthea Limited Sponsored ADR News

Opthea Limited Completes Nasdaq Delisting

Opthea Limited Sponsored ADR ( ($OPT) ) has issued an announcement. On November 21, 2025, Opthea Limited announced...

25d ago

OPT

Opthea Limited Announces Successful AGM Results

Opthea Limited Sponsored ADR ( ($OPT) ) has issued an announcement. On November 11, 2025, Opthea Limited held...

1M ago

OPT

Opthea Limited Schedules Virtual Annual General Meeting for November 2025

The latest announcement is out from Opthea Limited Sponsored ADR ( ($OPT) ). Opthea Limited has announced its...

2M ago

OPT

Opthea Limited Reports Improved Financial Results Amid R&D Challenges

Opthea Limited Sponsored ADR ( ($OPT) ) just unveiled an update. Opthea Limited reported its financial results for...

4M ago

OPT

Opthea terminates COAST trial, announces ShORe trial misses endpoint

Opthea (OPT) announced updates on its Phase 3 clinical program, including the termination of COAST and accelerated topline...

9M ago

OPT

Opthea downgraded to Perform from Outperform at Oppenheimer

Oppenheimer downgraded Opthea (OPT) to Perform from Outperform. Published first on TheFly – the ultimate source for real-time,...

9M ago

OPT

Opthea downgraded to Market Perform from Outperform at Leerink

Leerink analyst Marc Goodman downgraded Opthea (OPT) to Market Perform from Outperform. Published first on TheFly – the...

9M ago

OPT

Opthea cut to Market Perform at Leerink on failed sozinibercept trial

Leerink downgraded Opthea (OPT) to Market Perform from Outperform with a price target of $1, down from $12....

9M ago

OPT

Opthea double downgraded to Underperform from Buy at Jefferies

Jefferies double downgraded Opthea (OPT) to Underperform from Buy with a price target of $1, down from $8,...

9M ago

OPT

Opthea downgraded to Neutral from Buy at H.C. Wainwright

H.C. Wainwright analyst Matthew Caufield downgraded Opthea (OPT) to Neutral from Buy with a price target of $2,...

9M ago

OPT

CoreWeave initiated, Carvana upgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

9M ago

AJG

AON

Hold Rating Issued for Opthea Limited Amid Uncertainty Following Phase 3 Trial Failure

In a report released today, Matthew Caufield from H.C. Wainwright maintained a Hold rating on Opthea Limited Sponsored...

9M ago

OPT

Opthea Limited: Hold Rating Amid Phase 3 Trial Failure and Financial Uncertainty

In a report released yesterday, Marc Goodman from Leerink Partners downgraded Opthea Limited Sponsored ADR (OPT – Research...

9M ago

OPT

Opthea’s COAST Phase 3 Trial Fails to Meet Primary Endpoint, Raising Financial Concerns

Opthea Limited Sponsored ADR ( ($OPT) ) has shared an update. Opthea Limited announced that its COAST Phase...

9M ago

OPT

OPT FAQ

What was Opthea Limited Sponsored ADR’s price range in the past 12 months?

Opthea Limited Sponsored ADR lowest stock price was $0.02 and its highest was $6.30 in the past 12 months.

What is Opthea Limited Sponsored ADR’s market cap?

Opthea Limited Sponsored ADR’s market cap is $477.76M.

When is Opthea Limited Sponsored ADR’s upcoming earnings report date?

Opthea Limited Sponsored ADR’s upcoming earnings report date is Feb 26, 2026 which is in 73 days.

How were Opthea Limited Sponsored ADR’s earnings last quarter?

Opthea Limited Sponsored ADR released its earnings results on Aug 29, 2025. The company reported -$0.201 earnings per share for the quarter, missing the consensus estimate of -$0.07 by -$0.131.

Is Opthea Limited Sponsored ADR overvalued?

According to Wall Street analysts Opthea Limited Sponsored ADR’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Opthea Limited Sponsored ADR pay dividends?

Opthea Limited Sponsored ADR does not currently pay dividends.

What is Opthea Limited Sponsored ADR’s EPS estimate?

Opthea Limited Sponsored ADR’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Opthea Limited Sponsored ADR have?

Opthea Limited Sponsored ADR has 170,997,270 shares outstanding.

What happened to Opthea Limited Sponsored ADR’s price movement after its last earnings report?

Opthea Limited Sponsored ADR reported an EPS of -$0.201 in its last earnings report, missing expectations of -$0.07. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Opthea Limited Sponsored ADR?

Currently, no hedge funds are holding shares in OPT

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Opthea Limited Sponsored ADR

Opthea Limited Sponsored ADR (OPT) is a biotechnology company primarily engaged in the development of therapies to treat eye diseases, with a particular focus on wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The company's flagship product is OPT-302, a novel biologic therapy designed to inhibit vascular endothelial growth factors VEGF-C and VEGF-D, which play critical roles in the pathological formation of blood vessels in the eye.